Exact Mass: 452.2634716
Exact Mass Matches: 452.2634716
Found 225 metabolites which its exact mass value is equals to given mass value 452.2634716,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Repaglinide
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naive to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90\\% of a single orally administered dose is eliminated in feces and 8\\% in urine. C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is found in fruits. (14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is a constituent of Physalis peruviana (Cape gooseberry) Constituent of Physalis peruviana (Cape gooseberry). (14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is found in fruits.
PA(10:0/8:0)
C21H41O8P (452.25389160000003)
PA(10:0/8:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/8:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of caprylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/10:0)
C21H41O8P (452.25389160000003)
PA(8:0/10:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/10:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of capric acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
Tribendimidine
Tribendimidine is an orally active, broad-spectrum anthelmintic agent, with particularly high activity against A. lumbricoides and N. americanus. Tribendimidine is also an L-type nicotinic acetylcholine receptor (nAChR) agonist[1][2][3].
7-O-Demethylisocephaeline
A pyridoisoquinoline consisting of (1beta)-emetan substituted by hydroxy groups at positions 6 and 7 and methoxy groups at positions 10 and 11. It is isolated from Psychotria klugii and exhibits antileishmanial activity.
(E)-5-hydroxy-N-[3-[5-[3-[[(E)-5-hydroxy-3-methylpent-2-enoyl]amino]propyl]-3,6-dioxopiperazin-2-yl]propyl]-3-methylpent-2-enamide
2-Picenecarboxylic acid
(20R,22R)-21,24-epoxy-5beta-hydroxy-1-oxowitha-2,9(11),25(27)-trienolide|withametelinol-A
10-hidroxy 4,17-dihydro 17 beta-tchibangensine
C29H32N4O (452.25759819999996)
antidesmanin E|antidesmanin F|erythro-4-(2-(2-methoxy-4-((E)-3,3-dimethylpenta-1,4-dienyl)phenoxy)-1-hydroxy-3,3-dimethylpent-4-enyl)-2-methoxyphenol|threo-4-(2-(2-methoxy-4-((E)-3,3-dimethylpenta-1,4-dienyl)phenoxy)-1-hydroxy-3,3-dimethylpent-4-enyl)-2-methoxyphenol
(20R,22R)-17beta-hydroxy-1,12-dioxowitha-2,5,24-trien-26,22-olide|jaborosalactone 44
24,25,26,27-tetra-norapotirucalla-(apoeupha)-6alpha-acetoxy-7alpha-hydroxy-1,14,20,22-tetraen-21,23-epoxy-3-one|6alpha-O-acetyl-7-deacetylnimocinol
(22R)-4beta,27-dihydroxy-1-oxo-witha-2,5,16,24-tetraenolide|(4S,20S,22R)-4,27-dihydroxy-1-oxo-witha-2,5,16,24-tetraenolide
(20R,22R)-14,20-Dihydroxy-1-oxowitha-2,5,16,22-tetraenolide
3,22beta-dihydroxy-24,29-dinor-1(10),3,5-friedelatriene-2,7,21-trione
(22R,Z)-16beta,27-dihydroxy-1-oxo-witha-2,5,17(20),24-tetraenolide
3,7,9-trihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(20R,22R)-14,20-Dihydroxy-1-oxowitha-2,4,6,24-tetraenolide|14alpha,20alphaF-dihydroxy-1-oxo-22R-witha-2,4,6,24-tetraenolide
16-en-27-deoxywithaferin A|27-deoxy-Delta(16)-withaferin A|5beta,6beta-epoxy-4beta-hydroxy-1-oxo-witha-2,16,24-trienolide
1-(18-hydroxyoleoyl)-sn-glycrol 3-phosphate
C21H41O8P (452.25389160000003)
Repaglinide
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents CONFIDENCE standard compound; INTERNAL_ID 2189 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3349
C28H36O5_2-Picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,8,12b,13,14,14a,14b-tetradecahydro-10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-, (2R,4aS,6aS,12bR,14aS,14bR)
(2R,4aS,6aR,6aS,14aS,14bR)-10,11-dihydroxy-2,4a,6a,6a,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide
1-Propanol, 2-methoxy-3-[(9Z)-9-octadecenyloxy]-, dihydrogen phosphorothioate, (2R)
C22H45O5PS (452.27251700000005)
GDC-0349
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes. GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.
Etripamil
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Paraminabeolide F
A withanolide that is 18,22:23,26-diepoxyergosta-1,4-diene substituted by oxo groups at positions 3, 18 and 26. It has been isolated from a Formosan soft coral Paraminabea acronocephala.
2-Ethoxy-4-[2-[[3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
EleutherazineB
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D054659 - Diketopiperazines
[(2R)-2-hydroxy-3-phosphonooxypropyl] (Z)-18-hydroxyoctadec-9-enoate
C21H41O8P (452.25389160000003)
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(2-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(3-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(4-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
[(E)-2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1S,6R)-1,2,6-trimethylcyclohex-2-en-1-yl]oct-5-enyl] hydrogen sulfate
C25H40O5S (452.25963100000007)
(1-Acetyloxy-3-phosphonooxypropan-2-yl) hexadecanoate
C21H41O8P (452.25389160000003)
(2-Nonanoyloxy-3-phosphonooxypropyl) nonanoate
C21H41O8P (452.25389160000003)
(1-Phosphonooxy-3-propanoyloxypropan-2-yl) pentadecanoate
C21H41O8P (452.25389160000003)
(1-Hexanoyloxy-3-phosphonooxypropan-2-yl) dodecanoate
C21H41O8P (452.25389160000003)
(1-Butanoyloxy-3-phosphonooxypropan-2-yl) tetradecanoate
C21H41O8P (452.25389160000003)
(1-Heptanoyloxy-3-phosphonooxypropan-2-yl) undecanoate
C21H41O8P (452.25389160000003)
(1-Pentanoyloxy-3-phosphonooxypropan-2-yl) tridecanoate
C21H41O8P (452.25389160000003)
(1-Octanoyloxy-3-phosphonooxypropan-2-yl) decanoate
C21H41O8P (452.25389160000003)
[(2R)-2-octanoyloxy-3-phosphonooxypropyl] decanoate
C21H41O8P (452.25389160000003)
phosphatidic acid 18:0
C21H41O8P (452.25389160000003)
A phosphatidic acid in which the two acyl groups contain a total of 18 carbons and no double bonds.
GSK3326595
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5].
2-ethoxy-4-({[(1s)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]-c-hydroxycarbonimidoyl}methyl)benzoic acid
(1r,2r,8s,10r,11r,15r,16s)-15-(furan-3-yl)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadeca-3,12-dien-10-yl acetate
(1s,2s,4s,5s,8r,9s,10z,12r)-12-hydroxy-8-isopropyl-1,5,11-trimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-6,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate
(1r,5r,8r)-8-[(1r,3as,3bs,5as,9ar,11as)-5a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,6h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1s,2r,4r,6r,7s,10r,11r,16r,18r)-6-(furan-3-yl)-1,7,11,15,15-pentamethyl-14-oxo-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-12-en-18-yl acetate
6-(1-{3a-hydroxy-9a,11a-dimethyl-9-oxo-3h,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
(2-{2-[(1s,2r,4as,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl)oxysulfonic acid
C25H40O5S (452.25963100000007)
1-(furan-2-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
(2r,4as,6as,12br,14as,14br)-10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
(1r,3as,3br,9ar,9bs,11as)-1-[(1r)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-1-hydroxy-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,9bh,10h-cyclopenta[a]phenanthrene-9,11-dione
1-({3-ethyl-10-hydroxy-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol
6-(1-{6-hydroxy-9a,11a-dimethyl-9-oxo-3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
20-methyl-7,17,21,31-tetraazaoctacyclo[19.10.1.0³,¹⁹.0⁵,¹⁷.0⁶,¹⁴.0⁸,¹³.0²²,²⁷.0²⁸,³²]dotriaconta-6(14),8,10,12,18,22,24,26-octaen-11-ol
C29H32N4O (452.25759819999996)
(1s,2r,7s,9r,11s,12s,15r,16s)-2,16-dimethyl-15-[(1s,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one
4-[(1r,2r)-2-[4-(3,3-dimethylpenta-1,4-dien-1-yl)-2-methoxyphenoxy]-1-hydroxy-3,3-dimethylpent-4-en-1-yl]-2-methoxyphenol
3,10,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,10,12,12a,13,14-hexahydro-7h-picene-2,9-dione
(1s,3br,4r,5ar,9ar,9br,11s,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl acetate
17β-hydroxy-14α,20α-epoxy-1-oxo-(22r)-witha-3,5,24-trienolide
{"Ingredient_id": "HBIN001994","Ingredient_name": "17\u03b2-hydroxy-14\u03b1,20\u03b1-epoxy-1-oxo-(22r)-witha-3,5,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC1=C(C(=O)OC(C1)C2(C3(CCC4(C3(CCC5C4CC=C6C5(C(=O)CC=C6)C)C)O2)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10091","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5β,6β-epoxy-4β-hydroxy-1-oxowitha-2,14,24-trienolide
{"Ingredient_id": "HBIN011454","Ingredient_name": "5\u03b2,6\u03b2-epoxy-4\u03b2-hydroxy-1-oxowitha-2,14,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC12CC=C3C(C1CCC2C4COC5(CC4OC(=O)C5=C)C)CCC6(C3(C(=O)C=CC6)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7127","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5β,6β-epoxy-4β-hydroxy-1-oxo-witha-2,16,24-trienolide
{"Ingredient_id": "HBIN011455","Ingredient_name": "5\u03b2,6\u03b2-epoxy-4\u03b2-hydroxy-1-oxo-witha-2,16,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7128","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
6α-o-acetyl-7-deacetylnimocinol
{"Ingredient_id": "HBIN012215","Ingredient_name": "6\u03b1-o-acetyl-7-deacetylnimocinol","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "364","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
benzoylramanone
{"Ingredient_id": "HBIN017830","Ingredient_name": "benzoylramanone","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC(=O)C1CCC2(C1(C(CC3C2CC=C4C3(CCC(C4)O)C)OC(=O)C5=CC=CC=C5)C)O","Ingredient_weight": "452.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2268","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101974123","DrugBank_id": "NA"}
(1r,3ar,3br,4r,5ar,9ar,9br,11as)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-3,7-dioxo-1h,2h,3ah,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
12-hydroxy-8-isopropyl-1,5,11-trimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl 3-(1-methylimidazol-4-yl)prop-2-enoate
(2-{2-[(1s,2s,4ar)-1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl)oxysulfonic acid
C25H40O5S (452.25963100000007)
4,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,8,13,14,14b-octahydropicene-3,6-dione
(1r,5r,8r)-8-[(1r,3as,3bs,5r,9ar,9bs,11as)-5-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1r,3br,4s,5r,5ar,9ar,9br,11as)-1-(furan-2-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
(6bs,8ar,9s,11r,12as,12bs,14ar)-3,9,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
(1s,2r,7s,9r,11s,12s,15r,16s)-2,16-dimethyl-15-[(1r,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one
1-acetyl-3a,7-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl benzoate
[5-(furan-3-yl)-2-[2-(1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl)ethyl]pentyl]oxysulfonic acid
C25H40O5S (452.25963100000007)
7-[10-(5-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl)undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-3,7-dioxo-1h,2h,3ah,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(6bs,8ar,9s,11s,12as,12bs,14ar)-3,9,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
(1r,3ar,3br,4r,5as,9ar,9br,11as)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-3,7-dioxo-1h,2h,3ah,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
8-{11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
[(2s)-2-{2-[(1r,2r,4as)-1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl]oxysulfonic acid
C25H40O5S (452.25963100000007)
(1r,5s,8r)-8-[(1r,3as,3bs,9ar,9bs,11r,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(9r)-2,16-dimethyl-15-[(1r,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxatetracyclo[9.7.0.0³,⁹.0¹²,¹⁶]octadeca-2,4-dien-7-one
(1r)-1-{[(2s,3e,12bs)-3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl]methyl}-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-6-ol
C29H32N4O (452.25759819999996)
(1r,2r,10r,11s,14r,15s,16s)-16-[(2r)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,7-dien-9-one
(1r,5r,8r)-8-[(11r)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
[1-(2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl)-6-(furan-3-yl)-3-methylhexan-2-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
(1r,4s,5r,5ar,9ar,9br,11as)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
15-(furan-3-yl)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadeca-3,12-dien-10-yl acetate
[(1r,2s,4as,10br,12as)-8-hydroxy-2,4a,7,10b,12a-pentamethyl-9-oxo-1-(2-oxopropyl)-3,4,11,12-tetrahydro-1h-chrysen-2-yl]acetic acid
7,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,6,13,14,14b-octahydropicene-3,8-dione
(2r,4s,4ar,6as,12bs,14as,14bs)-4,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,8,13,14,14b-octahydropicene-3,6-dione
(6r)-6-{1-[(1z,2s,3as,3bs,9ar,9bs,11as)-2-hydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-ylidene]ethyl}-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
[(5e)-2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]oct-5-en-1-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
2,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-4,5,6,13,14,14b-hexahydro-1h-picene-3,8-dione
(2e)-n-{3-[(2r,5r)-5-(3-{[(2e)-1,5-dihydroxy-3-methylpent-2-en-1-ylidene]amino}propyl)-3,6-dihydroxy-2,5-dihydropyrazin-2-yl]propyl}-5-hydroxy-3-methylpent-2-enimidic acid
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11s,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1s,2s,4r,8r,9s,10z,12r)-12-hydroxy-8-isopropyl-1,5,11-trimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate
(1s,7s)-7-[(1e,3e,5e,7e,9e)-10-[(2r,3r,6r)-3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl]undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
[(2s,3r)-1-[(4as,8as)-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]-6-(furan-3-yl)-3-methylhexan-2-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
1-({3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl}methyl)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-6-ol
C29H32N4O (452.25759819999996)
4-[(1r,2r)-2-{4-[(1e)-3,3-dimethylpenta-1,4-dien-1-yl]-2-methoxyphenoxy}-1-hydroxy-3,3-dimethylpent-4-en-1-yl]-2-methoxyphenol
(6r)-6-[(1s)-1-[(3as,3bs,6s,9ar,9bs,11as)-6-hydroxy-9a,11a-dimethyl-9-oxo-3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
n-[3-(5-{3-[(1,5-dihydroxy-3-methylpent-2-en-1-ylidene)amino]propyl}-3,6-dihydroxy-2,5-dihydropyrazin-2-yl)propyl]-5-hydroxy-3-methylpent-2-enimidic acid
[(5e)-2-[3-(furan-3-yl)propyl]-6-methyl-8-(2,6,6-trimethylcyclohex-2-en-1-yl)oct-5-en-1-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
6-(1-{3a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3bh,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
(1s,3bs,4r,5s,5as,9as,9bs,11ar)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
6-(furan-3-yl)-1,7,11,15,15-pentamethyl-14-oxo-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-12-en-18-yl acetate
(1s,2r,6s,7r,9r,11s,12s,16s)-15-[(1s)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-6-hydroxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadeca-4,14-dien-3-one
(1r,2s,5s,6r,10r,11s,12r,15r,19s)-6-(furan-3-yl)-11-(methoxymethoxy)-1,5,10,15-tetramethyl-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadeca-8,16-dien-18-one
(3r,6s,8r,12s,15s,17r)-5,8,14,17-tetrahydroxy-3,12-bis(2-methylpropyl)-1,4,10,13-tetraazatricyclo[13.3.0.0⁶,¹⁰]octadeca-4,13-diene-2,11-dione
(1r,2r,10r,11s,14r,15s,16r)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-15-hydroxy-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,6-dien-9-one
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11r,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(10z)-12-hydroxy-8-isopropyl-1,5,11-trimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate
{2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]oct-5-en-1-yl}oxysulfonic acid
C25H40O5S (452.25963100000007)
1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
n-{1-[(2r,5s,6r)-5-{[(4s,5s,6r)-5-(dimethylamino)-4-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]-2-hydroxypyrimidin-4-ylidene}-2-methylpropanamide
(1r)-1-{[(2s,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-1,2,3,4-tetrahydroisoquinoline-6,7-diol
2,16-dimethyl-15-{1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl}-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one
methyl (6bs,8as,11r,12ar,12bs,14ar)-6b,8a,11,12b,14a-pentamethyl-2,4-dioxo-7h,8h,9h,10h,12h,12ah,13h,14h-phenanthro[2,1-f]isochromene-11-carboxylate
(1r,2r,10r,11s,14r,15s,16s)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-15-hydroxy-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,7-dien-9-one
(6s)-6-[(1r)-1-[(1s,6s,9ar,9bs,11as)-1,6-dihydroxy-9a,11a-dimethyl-9-oxo-2h,3h,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-3,4-dimethyl-5,6-dihydropyran-2-one
(1s,9r,11s,12s,15r,16s)-2,16-dimethyl-15-[(1r,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxatetracyclo[9.7.0.0³,⁹.0¹²,¹⁶]octadeca-2,4-dien-7-one
(2r,4as,6as,12br,14as,14br)-2,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-4,5,6,13,14,14b-hexahydro-1h-picene-3,8-dione
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11s,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(6bs,7s,8ar,9s,11r,12as,12bs,14as)-3,7,9-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(6bs,8ar,10s,11s,12as,12bs,14ar)-3,10,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,10,12,12a,13,14-hexahydro-7h-picene-2,9-dione
(1r)-1-{[(2s,3r,11bs)-3-ethyl-10-hydroxy-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol
(1r,4s,6r,7r)-7-[(1e,3e,5e,7e,9e)-10-[(2r,3s,6s)-3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl]undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
6-(1-{1,6-dihydroxy-9a,11a-dimethyl-9-oxo-2h,3h,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
3,7,9-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(1s,7s)-7-[(1e,3e,5e,7e,9e)-10-[(2s,5r,6r)-5-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl]undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
(1r,4r,5r,7s)-7-[(1r,3as,3bs,9ar,9bs,11as)-1-hydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3ah,3bh,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-4-hydroxy-4,5-dimethyl-2-oxabicyclo[3.2.1]octan-3-one
[8-hydroxy-2,4a,7,10b,12a-pentamethyl-9-oxo-1-(2-oxopropyl)-3,4,11,12-tetrahydro-1h-chrysen-2-yl]acetic acid
[(2s,5e)-2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1s)-2,6,6-trimethylcyclohex-2-en-1-yl]oct-5-en-1-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
(6r)-6-[(1r)-1-[(1s,3ar,3br,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3bh,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3,4-dimethyl-5,6-dihydropyran-2-one
6-(1-{2-hydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-ylidene}ethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
7-[10-(3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl)undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
(1s,2r,6s,7r,9r,11r,15r,16r)-15-[(1s)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-6-hydroxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadeca-4,12-dien-3-one
(1s,2r,4r,6s,7s,10r,11r,16r,18r)-6-(furan-3-yl)-1,7,11,15,15-pentamethyl-14-oxo-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-12-en-18-yl acetate
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11r,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(6r)-6-[(1r)-1-[(3ar,3br,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-9-oxo-3h,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3,4-dimethyl-5,6-dihydropyran-2-one
(1r,2r,10r,11s,14r,15r,16r)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-15-hydroxy-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,7-dien-9-one
(1s)-1-{[(2s,3e,12bs)-3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl]methyl}-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-6-ol
C29H32N4O (452.25759819999996)
(2-{2-[(1r,2r,4as)-1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl)oxysulfonic acid
C25H40O5S (452.25963100000007)
{2-[3-(furan-3-yl)propyl]-6-methyl-8-(2,6,6-trimethylcyclohex-2-en-1-yl)oct-5-en-1-yl}oxysulfonic acid
C25H40O5S (452.25963100000007)
1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol
(2s,3r,4s,11's,14's,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2',5',12'-triene-4',7'-dione
(1r,3br,4s,5r,5as,9ar,9br,11as)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
8-{5-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1's,2s,3r,4s,10'r,11'r,14's,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2',5',12'-triene-4',7'-dione
(6r)-6-[(1r)-1-[(1s,3br,9ar,9bs,11ar)-9a,11a-dimethyl-9-oxo-1h,2h,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
(1s)-1-{[(2s,3r,11bs)-3-ethyl-10-hydroxy-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol
2,16-dimethyl-15-{1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl}-8-oxatetracyclo[9.7.0.0³,⁹.0¹²,¹⁶]octadeca-2,4-dien-7-one
(1r,3br,4s,5r,5ar,9ar,9br,11as)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2',5',12'-triene-4',7'-dione
3,9,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
(1s,3as,3bs,7s,9ar,9bs,11r,11as)-1-acetyl-3a,7-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl benzoate
(2r,4as,6as,12bs,14as,14br)-7,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,6,13,14,14b-octahydropicene-3,8-dione
15-[1-(4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl)ethyl]-6-hydroxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadeca-4,14-dien-3-one
8-{11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
8-{5a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,6h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1r,2r,10r,11s,14r,15s,16s)-16-[(2r)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,6-dien-9-one
(1r,3br,4s,5r,5as,9ar,9br,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
4-hydroxy-7-{1-hydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3ah,3bh,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-4,5-dimethyl-2-oxabicyclo[3.2.1]octan-3-one
[(2s)-5-(furan-3-yl)-2-[2-(1,2,5,5-tetramethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl)ethyl]pentyl]oxysulfonic acid
C25H40O5S (452.25963100000007)